Department of Medicine, New York Medical College, Brander Cancer Research Institute, Hawthorne, New York, NY 10532, USA

Correspondence to: M V Blagosklonny, Brander Cancer Research Institute, New York Medical College, 19 Bradhurst Avenue, Hawthorne, New York, NY 10532, USA; E-mail: M_Blagosklonny@NYMC.EDU

By inducing p53-dependent G2 arrest, the pretreatment with low concentrations of DNA damaging drugs (e.g., doxorubicin, DOX) can prevent cell death caused by microtubule-active drugs (e.g., paclitaxel, PTX), thus potentially permitting selective killing of p53-deficient cancer cells. However, DOX still protects a subset of tumor cell lines lacking wt p53 (HL60 and Jurkat leukemia cells), thus limiting the utility of protection of cells with wt p53 (e.g., normal cells). The present work overcomes this obstacle by adding an abrogator of p53-independent checkpoint (e.g., UCN-01) to the DOX-PTX sequence. By inhibiting a p53-independent pathway, UCN-01 overrode DOX-induced G2 arrest and instead induced G1 arrest in HL60 and Jurkat, thus propelling these p53-deficient cells from G2 to G1. Once they entered mitosis, cells were killed by PTX. Induction of G2 arrest with sequential abrogation of a p53-independent checkpoint allows pharmacological manipulation of Raf-1/Bcl-2 hyperphosphorylation, PARP and Rb cleavage and cell death caused by PTX in p53-deficient cells. Unlike previous approaches, this strategy is intended to increase selectivity, not the cytotoxicity of PTX. This rational sequence of agents that induces p53-dependent and abrogates p53-independent arrest represents a cancerselective strategy for treatment of p53-deficient tumors.

Oncogene (2002) 21, 6249-6254. doi:10.1038/sj.onc.1205793

p53; mitosis; G2 arrest; checkpoints; paclitaxel